Patient Perspectives on Switching from Infliximab to Infliximab-dyyb in Patients with Rheumatologic Diseases in the United States.

Abstract

ObjectiveThe introduction of biosimilars for rheumatologic diseases (RDs) has provided a potentially lower‐cost therapy compared with their bio‐originator products; however, adoption of biosimilars may be challenged by patient perceptions. The objective of this study was to describe patients’ perspectives of switching from infliximab to infliximab‐dyyb.MethodsThis was a survey of adult patients with RDs who qualified for switching from infliximab to infliximab‐dyyb therapy between September 1 2017 and January 31 2018. Verbal consent was obtained prior to administration of a telephone survey. Survey questions were focused on the safety, efficacy, and knowledge of biosimilar therapy.ResultsA total of 108 patients were identified with 52 (48%) patients consenting to study participation. Forty (77%) and 12 (23%) patients reported switching and not switching, respectively, to infliximab‐dyyb. Regarding disease control, most respondents (80%) were satisfied to very satisfied with the switch to infliximab‐dyyb. Major concerns reported for switching included not knowing enough about the medication (38%), potential side effects (35%), and loss of disease activity control (35%).ConclusionOverall, patients reported satisfaction with switching from infliximab to infliximab‐dyyb, but concerns regarding safety and efficacy were expressed. Patient involvement in the switching decision‐making process may allay concerns and enhance biosimilar uptake.